CalciMedica is trading at $1.08, up 5.88%, in line with biotech-sector strength rather than a verified fresh company-specific catalyst.
- XBI is up 2.10%, alongside reported biotech M&A activity.
- No verified October 20 company-specific announcement was identified; FDA trial-design news dates to July. Shares closed at $1.02 on October 19 after several declining sessions, making today’s gain a reversal. No verified volume or further company-specific explanation was found.